Store

Home | Store | The Market for Molecular Point-of-Care (mPOC), 2022

The Market for Molecular Point-of-Care (mPOC), 2022

Publication Date: March 24, 2022

SKU: 22-018

Tags: COVID-19, Diagnostic Instruments, Molecular Diagnostics, Point-of-Care (POC) Testing

Pages: 125

SKU: 22-018

Kalorama Information’s The Market for Molecular Point-of-Care (mPOC), 2022 is an invaluable resource for stakeholders in the mPOC market, providing the most current and comprehensive analysis of the industry’s trends, technologies, and market dynamics, including market sizing, forecasting, trend analysis, and competitive landscape evaluation.

 

Report Highlights:

  • Market Overview:
    • Detailed analysis of the market for molecular point of care tests utilizing PCR or other molecular technologies known for their rapid turnaround times and suitability for near-patient settings.
    • Examination of major industry players such as Abbott, Roche, and Quidel, along with many emerging competitors since our last report.
  • Technological Advancements:
    • Focus on mPOC systems that deliver faster and more accurate results compared to traditional lab-based tests and existing point of care systems.
    • Exploration of ongoing developments and menu expansions within the mPOC segment.
  • Defining mPOC:
    • Clear definition of mPOC systems, characterized by their ability to perform DNA and RNA testing on compact devices designed for use outside of reference labs.
    • Emphasis on the rapid result times, typically within the duration of an office visit or bedside consultation, facilitated by user-friendly cartridges and minimal preparation steps.
  • Impact of COVID-19:
    • In-depth analysis of how the COVID-19 pandemic has accelerated the adoption and development of mPOC systems.
    • Coverage of the significant role rapid PCR testing has played during the pandemic, meeting the demand for timely and accurate diagnostics.

 

Market Insights:

  • Data and Competitive Analysis:
    • Detailed data on current mPOC systems and competitor landscape.
    • Market size and growth projections from 2021 to 2026, including specific focus on the COVID-19 mPOC market.
    • Breakdown of market share by vendor, geographic regions, and market segments.
  • Segment Analysis:
    • Detailed segmentation of the molecular point of care market, including respiratory and other applications.
    • Analysis of the respiratory segment, covering specific conditions like Flu, RSV, and Strep.
    • Geographic and segment breakouts of market data for 2021, including North America, Europe, APAC, and Rest of World (RoW).

 

Strategic Insights:

  • Trends and Developments:
    • Exploration of key trends such as menu expansion, disease statistics, and the competitive landscape amidst the COVID-19 crisis.
    • Examination of immunoassay competition and enhancements, emerging markets, and recent journal studies on the efficacy of mPOC systems.

 

Table: Molecular Point of Care Market, 2021-2026 (in millions $)

Year Revenues Growth
2021 $XX Million XX%
2022 $XX Million XX%
2023 $XX Million XX%
2024 $XX Million XX%
2025 $XX Million XX%
2026 $XX Million XX%
CAGR $XX Million XX%

Source: Kalorama Information

For further details and to purchase directly, please contact us.

Table of Contents

Chapter One: Executive Summary

  • Figure 1-1: Molecular Point of Care Market, 2021-2026

Where is Molecular Point of Care in 2021?

Molecular Point of Care Market Analysis

  • Figure 1-2: mPOC Market by Disease Indication, 2020 (%; Respiratory, Other)

Market Observations

“Near-Patient” Molecular Systems Market

  • Figure 1-3: mPOC and Near-Patient Market, 2021-2026
  • Table 1-1: Near Patient Molecular Systems Market: 2021-2026 ($M)

Current Trends

Molecular Point-of-Care Diagnostics Defined

Usage of Molecular Point of Care

Leading mPOC Platforms

  • Table 1-2: Molecular POC Diagnostic Platforms/ Technologies

Trends

Scope and Methodology

 

Chapter Two: Molecular Point-of-Care Market Development and Trends

COVID-19 and Molecular POC

  • Table 2-1: Molecular POC COVID-19 Emergency Authorizations

CDC Initial Response, Long Term Situation

COVID-19’s Unique Challenge

BARDA Directs Funding to mPOC

Recent Regulatory Developments

Consortia, Funding, Prizes

Deals

  • Table 2-2: Deals in Molecular Point of Care

Advantages and Disadvantages of Molecular Point of Care

  • Table 2-3: Disadvantages of Molecular Point of Care, by Setting

Justification: The Sensitivity/Specificity Argument

New Systems and Menu Expansion

Mesa Biotech Strep A Approval

Combination Tests Enter Market: SARS-CoV-2, Flu A, Flu B, and RSV

STI Continues to Be a Growth Area

Deals, Investment in mPOC Systems

Thermo Acquires Mesa Biotech

EU Researchers Awarded €3M to Develop POC Molecular Tests

Scope Fluidics AST System Sees Investment

China as a POC Market

Common Tests and Analytes in POC Diagnostics

Component Technologies of Molecular Point-of-Care Diagnostics

Microfluidics

qPCR

Microarrays

Isothermal Amplification

Test Automation

Primers and Probes

Detection

Next-Generation Sequencing

Molecular Diagnostics

Real-Time PCR (qPCR)

Isothermal Amplification Methods

Line Probe Assays

Next-Generation Sequencing

Applications and Potential Applications for Molecular Point-of-Care

Major Testing Applications for Molecular POC Diagnostics

Influenza

Reclassification of RIDTs

Hospital-Acquired Infections (HAIs)

Strep A

Respiratory Syncytial Virus (RSV)

Emerging Applications

Zika

Other Respiratory Infections

Group B Streptococcus

Human Papillomavirus

Herpes Simplex Virus

Vaginitis

Malaria

Other Tropical and Neglected Diseases

Cancer

European Device Regulations Nearing

 

Chapter Three: Market Analysis

Molecular Point of Care Market Analysis

  • Table 3-1: Molecular Point of Care Market: 2021-2026
  • Table 3-2: Molecular Point of Care Market Share by Vendor, 2021 ($M, %)
  • Figure 3-1: Molecular Point of Care Market Share by Vendor, 2021 (%)
  • Table 3-3: Geographic Breakout of the Molecular Point of Care Market, 2021 (N. America, Europe, APAC, RoW)
  • Table 3-4: Segment Breakout of Molecular Point of Care Market, 2021 (Respiratory vs. Other)
  • Figure 3-2: Breakout of Molecular Point of Care Market, 2021 (%; Respiratory, Other)

“Near Patient Molecular” Market

  • Table 3-5: Near Patient Molecular Systems Market: 2021-2026

Market Share Near Patient

  • Figure 3-3:  Market Share, Near Patient Molecular Testing, 2021

 

Chapter Four: Company Profiles

Abbott Laboratories

Aidian Oy

Akonni Biosystems

binx health, inc.

Biocartis NV

bioMérieux SA

Cepheid (Danaher)

Molecular Healthcare-Acquired Infection (HAI) Testing

Molecular Sexual Health and Women’s Health Testing

Molecular Critical Infectious Disease Testing

Molecular Oncology/Genetics Testing

Credo Diagnostics

Curetis NV (OpGen)

DiaSorin S.p.A

GenMark Diagnostics (Roche)

Greiner Bio-One GmbH

Meridian Bioscience, Inc.

Mesa Biotech, Inc. (Thermo)

QIAGEN NV

QuantuMDx Group

Quidel Corporation

Roche

Sekisui Diagnostics LLC

T2 Biosystems

Our Knowledge Center provides access to

all market reports